{
    "root": "2eacec81-3528-a573-e063-6394a90a6da4",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ivabradine",
    "value": "20250224",
    "ingredients": [
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "GLYCERYL MONOCAPRYLOCAPRATE",
            "code": "G7515SW10N",
            "drugbank_id": "https://go.drugbank.com/drugs/DB19362"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "POLYVINYL ALCOHOL GRAFT POLYETHYLENE GLYCOL COPOLYMER (3:1; 45000 MW)",
            "code": "23ZQ42JZZH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "IVABRADINE HYDROCHLORIDE",
            "code": "TP19837BZK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_85969"
        }
    ],
    "indications": {
        "text": "ivabradine hyperpolarization-activated cyclic nucleotide\u2011gated channel blocker indicated : reduce risk hospitalization worsening heart failure adult patients stable , symptomatic chronic heart failure reduced left ventricular ejection fraction . ( 1.1 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "chronic heart failure",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_294422"
            }
        ]
    },
    "contraindications": {
        "text": "adult patients starting dose 2.5 ( vulnerable adults ) 5 mg twice daily food . 2 weeks treatment , adjust dose based heart rate . maximum dose 7.5 mg twice daily . ( 2.1 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "ivabradine tablets 5 mg formulated orange-colored , oval-shaped , film-coated tablets functionally scored edges , marked \u201c i5 \u201d one face bisected face . supplied follows : bottles 60 tablets child-resistant closure ( ndc 69452-190-17 ) bottles 500 tablets ( ndc 69452-190-30 ) ivabradine tablets 7.5 mg formulated orange-colored , triangular-shaped , film-coated tablets debossed \u201c 7.5 \u201d one face plain face . supplied follows : bottles 60 tablets child-resistant closure ( ndc 69452-191-17 ) bottles 500 tablets ( ndc 69452-191-30 ) storage store ivabradine tablets 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "ivabradine contraindicated patients : acute decompensated heart failure clinically significant hypotension sick sinus syndrome , sinoatrial block 3 rd degree av block , unless functioning demand pacemaker present clinically significant bradycardia [ ( 5.3 ) ] severe hepatic impairment [ ( 8.6 ) ] pacemaker dependence ( heart rate maintained exclusively pacemaker ) [ ( 7.3 ) ] concomitant strong cytochrome p450 3a4 ( cyp3a4 ) inhibitors [ ( 7.1 ) ]",
    "indications_original": "Ivabradine is a hyperpolarization-activated cyclic nucleotide\u2011gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. ( 1.1 )",
    "contraindications_original": "Adult patients Starting dose is 2.5 (vulnerable adults) or 5 mg twice daily with food. After 2 weeks of treatment, adjust dose based on heart rate. The maximum dose is 7.5 mg twice daily. ( 2.1 )",
    "warningsAndPrecautions_original": "Ivabradine tablets\u00a05 mg are formulated as orange-colored, oval-shaped, film-coated tablets functionally scored on both edges, marked with \u201cI5\u201d on one face and bisected on the other face.\u00a0\u00a0They are supplied as follows:\n                  \n                     Bottles of 60 tablets\u00a0with child-resistant closure (NDC 69452-190-17)\n                     Bottles of\u00a0500 tablets (NDC 69452-190-30)\n                  \n                  Ivabradine\u00a0tablets 7.5 mg are formulated as orange-colored, triangular-shaped, film-coated tablets debossed with \u201c7.5\u201d on one face and plain on the other face. \u00a0They are supplied as follows:\n                  \n                     Bottles of 60 tablets\u00a0with child-resistant closure (NDC 69452-191-17)\n                     Bottles of\u00a0500 tablets (NDC 69452-191-30)\n                  \n                  \n                     \n                        Storage\n                     \n                  \n                  Store ivabradine tablets at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Ivabradine\u00a0is contraindicated in patients with:\n                  \n                     Acute decompensated heart failure\n                     Clinically significant hypotension\n                     Sick sinus syndrome, sinoatrial block or 3\n  \n   rd\u00a0degree AV block, unless a functioning demand pacemaker is present\n \n  \n                     Clinically significant bradycardia\n  \n   [see Warnings and Precautions (\n   \n    5.3)]\n  \n   \n                     \n                     Severe hepatic impairment\n  \n   [see Use in Specific Populations (\n   \n    8.6)]\n  \n   \n                     \n                     Pacemaker dependence (heart rate maintained exclusively by the pacemaker)\n  \n   [see Drug Interactions (\n   \n    7.3)]\n  \n   \n                     \n                     Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors\n  \n   [see Drug Interactions (\n   \n    7.1)]",
    "drug": [
        {
            "name": "ivabradine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_85966"
        }
    ]
}